Natixis’s Immunovant IMVT Stock Holding History

Natixis’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28M	Buy	+830,000	New	+$32.7M	0.1%	136

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Natixis's IMVT Position: Q1 2024 in Review

Natixis sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 16,900 shares — an estimated $712K sold.

Natixis first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $712K in Q4 2023. 210 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Natixis reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Natixis sold 16,900 Immunovant shares in Q1 2024, an estimated $712K.
Natixis first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
Natixis's Immunovant position peaked at $712K in Q4 2023.
210 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.